Bergen, 15. April 2024 – Det vises til børsmeldingen fra BerGenBio ASA (“Selskapet”) datert 2. April 2024 vedrørende start av den siste utøvelsesperioden for de frittstående tegningsrettene (de “Frittstående Tegningsrettene”) utstedt i forbindelse med fortrinnsrettsemisjonen som reiste bruttoproveny på NOK 250 millioner (“Fortrinnsrettsemisjonen”). De Frittstående Tegningsrettene var noterte fra 23. juni 2023 og kunne handles på Oslo Børs frem til kl 16:30 (CEST) den 8. april 2024 under ticker-koden “BGBIS”. Hver Frittstående Tegningsrett gir innehaveren rett til å tegne en ny aksje i Selskapet i løpet av to utøvelsesperioder, hvorav den første utøvelsesperioden har passert (slike nye aksjer omtales samlet som de “Nye Aksjene”).

Den siste utøvelsesperioden for de Frittstående Tegningsrettene avsluttes i dag, den 15. April 2024 kl. 16.30 (CEST).

Gjenstående Frittstående Tegningsretter kan utøves ved innsendelse av en korrekt utfylt utøvelsesblankett (“Utøvelsesblanketten”) til en av Arctic Securities AS eller Carnegie AS (i fellesskap omtalt som “Tilretteleggerne”) på adressen eller e-postadressen angitt i prospektet utarbeidet i forbindelse med Fortrinnsrettsemisjonen datert 26. mai 2023 (“Prospektet”) eller i Utøvelsesblanketten, eller elektronisk gjennom VPS’ online tegningssystem i løpet av den siste utøvelsesperiodene for de Frittstående Tegningsrettene.

Instruksjoner hvordan utøve tegningsrettene, Utøvelsesblanketten og link til VPS elektronisk tegningssystem kan finnes på nettsidene til Selskapet (https://www.bergenbio.com/investors/investor-relations/norwegian-warrants), Carnegie AS (www.carnegie.no/ongoing-prospectuses-and-offerings/) og Arctic Securities AS (www.arctic.com/offerings).

Ved å fylle ut og sende inn en Utøvelsesblankett eller tegne elektronisk via VPS, forplikter innehaveren av Frittstående Tegningsretter seg til å tegne et antall Nye Aksjer tilsvarende det antall Frittstående Tegningsretter som utøves til utøvelsesprisen på NOK 0,1255 pr. Nye Aksje.

For ytterligere informasjon, vennligst kontakt:

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.no

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Media Relations

Jan Lilleby

jl@lillebyfrisch.no

For informasjon om de Frittstående Tegningsrettene, vennligst kontakt en av Tilretteleggerne:

Arctic Securities AS, tel.: + 47 21 01 30 40

Carnegie AS, tel.: +47 22 00 93 40

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate bemcentinib a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and severe respiratory infections. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The Company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com.

– IMPORTANT INFORMATION –

This announcement does not constitute an offer of securities for sale or a solicitation of an offer to purchase securities of the Company in the United States or any other jurisdiction. The securities of the Company may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the “U.S.Securities Act”). The securities of the Company have not been, and will not be, registered under the U.S. Securities Act. Any sale in the United States of the securities mentioned in this communication will be made solely to “qualified institutional buyers” as defined in Rule 144A under the U.S. Securities Act. No public offering of the securities will be made in the United States.

This announcement has been prepared on the basis that any offer of securities in any Member State of the European Economic Area, other than Norway, which has implemented the Prospectus Regulation (EU) (2017/1129, as amended, the “Prospectus Regulation”) (each, a “Relevant Member State”) will be made pursuant to an exemption under the Prospectus Regulation, as implemented in that Relevant Member State, from the requirement to publish a prospectus for offers of securities. Accordingly any person making or intending to make any offer in that Relevant Member State of securities which are the subject of the offering contemplated in this announcement, may only do so in circumstances in which no obligation arises for the Company or any of the Managers to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 16 of the Prospectus Regulation, in each case, in relation to such offer.

In the United Kingdom, this announcement is only addressed to and is only directed at Qualified Investors who (i) are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the “Order”) or (ii) are persons falling within Article 49(2)(a) to (d) of the Order (high net worth companies, unincorporated associations, etc.) (all such persons together being referred to as “Relevant Persons”). This announcement are directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this announcement relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. Persons distributing this communication must satisfy themselves that it is lawful to do so.

Matters discussed in this announcement may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as “anticipate”, “believe”, “continue”, “estimate”, “expect”, “intends”, “may”, “should”, “will” and similar expressions. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond its control. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The information, opinions and forward-looking statements contained in this announcement speak only as at its date, and are subject to change without notice.

This announcement is made by and, and is the responsibility of, the Company. The Managers are acting exclusively for the Company and no one else and will not be responsible to anyone other than the Company for providing the protections afforded to their respective clients, or for advice in relation to the contents of this announcement or any of the matters referred to herein.

Neither the Managers nor any of their respective affiliates makes any representation as to the accuracy or completeness of this announcement and none of them accepts any responsibility for the contents of this announcement or any matters referred to herein.

This announcement is for information purposes only and is not to be relied upon in substitution for the exercise of independent judgment. It is not intended as investment advice and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of an offer to buy any securities or a recommendation to buy or sell any securities of the Company. Neither the Managers nor any of their respective affiliates accepts any liability arising from the use of this announcement. Any offering of the securities referred to in this announcement will be made by means of a prospectus.

This announcement is an advertisement and is not a prospectus for the purposes of the Prospectus Regulation. Investors should not subscribe for any securities referred to in this announcement except on the basis of information contained in the Prospectus dated 26 May 2023 and stock exchange announcements published in connection with the Rights Issue and the Warrants. Copies of the Prospectus is available from the Company’s registered office and, subject to certain exceptions, on the websites of the Company Company (https://www.bergenbio.com/investors/investor-relations/warrants), Carnegie AS (www.carnegie.no/ongoing-prospectuses-and-offerings/) and Arctic Securities AS (www.arctic.com/offerings).

Each of the Company, the Managers and their respective affiliates expressly disclaims any obligation or undertaking to update, review or revise any statement contained in this announcement whether as a result of new information, future developments or otherwise.

The distribution of this announcement and other information may be restricted by law in certain jurisdictions. Persons into whose possession this announcement or such other information should come are required to inform themselves about and to observe any such restrictions.

This information is published in accordance with the requirements of the Continuing Obligations.